Paolo Bidoli
University of Milano-Bicocca
103 Papers
571 Citations
Paolo Bidoli is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Lung cancer & Population. The author has an hindex of 27, co-authored 103 publications.
Chat about Author
Papers
1263pafatinib (a) followed by a + paclitaxel (p) or investigator's choice of single-agent chemotherapy (ic) in patients (pts) with advanced squamous cell carcinoma (scc) of the lung: subgroup analysis of lux-lung 5 (ll5)
K. Park,Jai Keun Kim,Martin Schuler,David Planchard,F. De Marinis,Yuh Min Chen,C. Zhou,Jaafar Bennouna,L. Xiaoqing,Ji Feng Feng,Paolo Bidoli,János Strausz,Christos Chouaid,Ming Shyan Huang,L. Ho,Bushi Wang,Vikram K. Chand,J.C.-H. Yang +17 more
TL;DR: In this small group of pts with SCC, the authors observed prolonged PFS, higher OR and trend towards longer OS in patients treated with A + P vs IC following A, and signs of activity in this difficult-to-treat population are encouraging.
5
Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.
Lucio Crinò,Paolo Bidoli,Angelo Delmonte,Francesco Grossi,Filippo de Marinis,Francesca Sperandi,Fabiana Vitiello,Milena Vitali,Hector Soto Parra,Simone Scagnoli,Gabriele Minuti,Luana Calabrò,Marcello Tiseo,Daniele Turci,Silvia Quadrini,Paola Antonelli,Anna Manzo,Irene Prediletto,Diana Giannarelli,Domenico Galetta +19 more
TL;DR: Nivolumab is the first checkpoint inhibitor approved for the treatment of squamous non small cell lung cancer to show a survival benefit in a randomised phase III trial.
5
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC).
Ignazio Cataldo,Amedeo Vittorio Bedini,Giuseppe Muscolino,Maurizio Valente,Ugo Pastorino,Paolo Bidoli,Silvana Pilotti,Gianni Ravasi +7 more
TL;DR: From 1981 to 1986, 17 patients with resected small cell lung carcinoma (SCLC) staged as I or II according to the new TNM classification were recruited for a prospective study to evaluate the effctiveness of surgery and postoperative chemotherapy in the treatment of early stages of the disease.
5
Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM→ docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non small cell lung cancer (NSCLC)
Paolo Bidoli,Diego Cortinovis,L. Isa,Alberto Fusi,F. Pari,D. Cullurà,Enrico Aitini,S. Pessa,Barbara Formisano,Emilio Bajetta +9 more
TL;DR: In this article, the authors show that platinum analogues have shown good activity and better toxicity profile than cisplatin/GEM regimens in advanced NSCLC, while sequential administration of two platinum/non-platinum...
4
Pilot study with adriamycin and ifosfamide in small cell lung cancer.
Paolo Bidoli,Silvia Spinazzé,Armando Santoro,Amedeo Vittorio Bedini,Ignazio Cataldo,Gianni Bonadonna +5 more
TL;DR: The high response rate achieved after four cycles and the low incidence of marrow toxicity suggest the use of this regimen for a short period with increased dose levels.
4